Literature DB >> 23917591

[Lead survival and complications (except infections). Are we doing better nowadays?].

Martin Seifert1, Michael Neuss, Maren Schöpp, Cornel Koban, Christian Butter.   

Abstract

In the last decade manufacturers of cardiac rhythm management devices focused mainly on the reduction of both device and lead size. Furthermore the implementation of additional functions like cardiac monitoring and new algorithms as well as increasing defibrillation safety through higher energy delivery became of greater interest. The FDA recall (class I) of some of the commonly used ICD leads led to a change in thinking in ICD therapy, more attention to device and lead function control in addition to the increased awareness of lead complications. These issues changed our daily behaviour in ICD implantation and follow up effectively. The following article gives an overview of ICD lead performance, suitable recalls, complications as well as available control functions. The need for improved market supervision of lead function in the medical community and proven alternative device therapies for selected patients is being discussed.

Entities:  

Mesh:

Year:  2013        PMID: 23917591     DOI: 10.1007/s00399-013-0278-2

Source DB:  PubMed          Journal:  Herzschrittmacherther Elektrophysiol        ISSN: 0938-7412


  32 in total

1.  Transvenous implantable cardioverter-defibrillator leads: the weakest link.

Authors:  William H Maisel
Journal:  Circulation       Date:  2007-05-15       Impact factor: 29.690

2.  Risk of failure of transvenous implantable cardioverter-defibrillator leads.

Authors:  C Jan Willem Borleffs; Lieselot van Erven; Rutger J van Bommel; Enno T van der Velde; Ernst E van der Wall; Jeroen J Bax; Frits R Rosendaal; Martin J Schalij
Journal:  Circ Arrhythm Electrophysiol       Date:  2009-04-17

3.  Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.

Authors:  Arthur J Moss; Wojciech Zareba; W Jackson Hall; Helmut Klein; David J Wilber; David S Cannom; James P Daubert; Steven L Higgins; Mary W Brown; Mark L Andrews
Journal:  N Engl J Med       Date:  2002-03-19       Impact factor: 91.245

4.  Impact of implanted recalled sprint Fidelis lead on patient mortality.

Authors:  Thomas B Morrison; Paul A Friedman; Linda M Kallinen; David O Hodge; Daniel Crusan; Kapil Kumar; David L Hayes; Robert F Rea; Robert G Hauser
Journal:  J Am Coll Cardiol       Date:  2011-07-12       Impact factor: 24.094

5.  ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 appropriate use criteria for implantable cardioverter-defibrillators and cardiac resynchronization therapy: a report of the American College of Cardiology Foundation appropriate use criteria task force, Heart Rhythm Society, American Heart Association, American Society of Echocardiography, Heart Failure Society of America, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance.

Authors:  Andrea M Russo; Raymond F Stainback; Steven R Bailey; Andrew E Epstein; Paul A Heidenreich; Mariell Jessup; Suraj Kapa; Mark S Kremers; Bruce D Lindsay; Lynne Warner Stevenson
Journal:  J Am Coll Cardiol       Date:  2013-03-01       Impact factor: 24.094

6.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.

Authors:  Gust H Bardy; Kerry L Lee; Daniel B Mark; Jeanne E Poole; Douglas L Packer; Robin Boineau; Michael Domanski; Charles Troutman; Jill Anderson; George Johnson; Steven E McNulty; Nancy Clapp-Channing; Linda D Davidson-Ray; Elizabeth S Fraulo; Daniel P Fishbein; Richard M Luceri; John H Ip
Journal:  N Engl J Med       Date:  2005-01-20       Impact factor: 91.245

7.  Generator exchange is associated with an increased rate of Sprint Fidelis lead failure.

Authors:  Joshua D Lovelock; Ayesha Patel; Andenet Mengistu; Michael Hoskins; Mikhael El-Chami; Michael S Lloyd; Angel Leon; David DeLurgio; Jonathan J Langberg
Journal:  Heart Rhythm       Date:  2012-06-06       Impact factor: 6.343

8.  Fluoroscopic screening of asymptomatic patients implanted with the recalled Riata lead family.

Authors:  Jeffrey Liu; Rohit Rattan; Evan Adelstein; William Barrington; Raveen Bazaz; Susan Brode; Sandeep Jain; G Stuart Mendenhall; Jan Nemec; Eathar Razak; Alaa Shalaby; David Schwartzman; Andrew Voigt; Norman C Wang; Samir Saba
Journal:  Circ Arrhythm Electrophysiol       Date:  2012-07-11

9.  Survival of patients receiving a primary prevention implantable cardioverter-defibrillator in clinical practice vs clinical trials.

Authors:  Sana M Al-Khatib; Anne Hellkamp; Gust H Bardy; Stephen Hammill; W Jackson Hall; Daniel B Mark; Kevin J Anstrom; Jeptha Curtis; Hussein Al-Khalidi; Lesley H Curtis; Paul Heidenreich; Eric D Peterson; Gillian Sanders; Nancy Clapp-Channing; Kerry L Lee; Arthur J Moss
Journal:  JAMA       Date:  2013-01-02       Impact factor: 56.272

10.  Deaths caused by the failure of Riata and Riata ST implantable cardioverter-defibrillator leads.

Authors:  Robert G Hauser; Raed Abdelhadi; Deepa McGriff; Linda Kallinen Retel
Journal:  Heart Rhythm       Date:  2012-03-23       Impact factor: 6.343

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.